A newly engineered antibody can penetrate kidney cysts and interrupt the growth signals that drive polycystic kidney disease.

PKD is mainly caused by mutations in the PKD1 and PKD2 genes, affecting polycystin proteins. Disrupted signaling pathways, like cAMP and vasopressin, are major drivers of cyst growth. Tolvaptan is ...

A prolonged course of antibiotic therapy dramatically reduces the risk of recurrence in patients with renal cyst infections in the context of autosomal dominant polycystic kidney disease (ADPKD), a ...

Polycystic kidney disease (PKD) causes round, fluid-filled sacs called cysts to grow in your kidneys. These cysts can cause your kidneys to enlarge and function poorly. People with PKD can also ...

Polycystic kidney disease (PKD) is a genetic disorder marked by the growth of many fluid-filled sacs (cysts) in your kidneys. These cysts can grow to replace normal kidney tissue over time, leading to ...

MIT researchers including Robert Croy (left) and Bogdan Fedeles have discovered that a drug they originally developed as a potential cancer treatment may also hold promise in treating autosomal ...

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 ...

Their results indicated that cMET activity was inhibited, which in turn lowered the cell growth signals. Not only that, but according to the paper, the treatment appears also to have triggered a ...